drugset / Trial / NCT01720043
Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the effect of VELCADE on platelet aggregation at baseline, 24 hours and 48 hours after infusion in patients with multiple myeloma
Timeline
- Start
- 2013-07
- Primary completion
- 2015-04
- Completion
- 2017-07
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1 mg/m2 | — |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | — |